# Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

> **NCT02452281** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Rabih Said**

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** ipilimumab
- **DRUG:** HSPPC-96

## Key facts

- **NCT ID:** NCT02452281
- **Lead sponsor:** Rabih Said
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI departure, operational issues
- **Last updated:** 2016-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452281, "Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02452281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*